Skip to content

A Clinical trial of Shleshmatakadhya Agada on Non-Alcoholic Fatty Liver Disease(NAFLD)

Evaluation of Shleshmatakadhya Agada on Aamvishjanya Yakrit Roga (Non-Alcoholic Fatty Liver Disease)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/036036
Enrollment
30
Registered
2021-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Sponsors

Vanya Gupta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Metabolic disorders like Obesity, Dyslipidemia, etc. are considered, and if any three or more out of the following five criteria are present like: a)Waist circumference over 40 inches (men) or 35 inches (women), b)Blood pressure over 130/86 mmHg (includes up to 140/90 mm Hg), c)Fasting triglyceride (TG) level over 150 mg/dl (includes up to 200 mg/dl), d)Fasting high-density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) [includes not below than 30 mg/dl] and e)Fasting blood sugar up to 110 mg/dl. 2.Serum Glutamic Pyruvic Transaminase (SGPT) elevated more than 60 IU, ( 3.BMI > 25kg/m2 4.Classical symptoms of Yakrit Roga like Aruchi, Hrillaasa evam Chardii , Avipaka , Daurbalya evam Shrama , Udara shoola, Vibandha , Asya-vairasya , Anaha mentioned as per the classical Ayurvedic texts

Exclusion criteria

Exclusion criteria: 1.Pregnant women, children, old aged persons and Pre diagnosed cases of serious metabolic disorders like Hypertension, Diabetes Mellitus, Hypothyroidism. 2.Pre diagnosed cases of Hyperbilirubinemia, Viral Hepatitis, Liver cirrhosis, and Hepatocellular carcinoma, 3.Immuno-compromised condition and other systemic infection. 4.SGPT > 100 IU

Design outcomes

Primary

MeasureTime frame
To assess the effect of therapy , objectively all signs and symptoms were given scoring depending upon their severity. Complete Remission- 100% Maximum Improvement- 75-99% Moderate Improvement- 50-74% Mild Improvement- 25-49% No Improvement- 0-24%Timepoint: Outcome will be assessed after completion of 3 months trial in all the 30 patients.

Secondary

MeasureTime frame
Excerberation of sign and symptomsTimepoint: 1 month

Countries

India

Contacts

Public ContactVed Bhushan Sharma

Rishikul Campus, U.A.U.,Haridwar

ved.parul@gmail.com9045042479

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026